A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2748-2755

  Kossman, S E ^a   Scheinberg, D A ^a   Jurcic, J G ^a   Jimenez, J ^a   Caron, P C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M 195; RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FEVER; FLOW CYTOMETRY; HUMAN; HYPOTENSION; IMMUNOPHENOTYPING; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; SKIN DEFECT; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD56; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; FEMALE; HUMANS; INTERLEUKIN-2; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED;

EID: 0032724046     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Tanimoto, M., Scheinberg, D. A., Cordon-Cardo, C., Huie, D., Clarkson, B. D., and Old, L. J. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia, 3: 339-348, 1989.
2. Scheinberg, D. A., Tanimoto, M., McKenzie, S., Strife, A., Old, L. J., and Clarkson, B. D. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia, 3: 440-445, 1989.
3. Griffen, J. D., Ritz, J., Nadler, L. M., and Schlossman, S. F. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J. Clin. Investig., 68: 932-941, 1981.
4. Scheinberg, D. A., Lovett, D., Divgi, C. R., Graham, M. C., Berman, E., Pentlow, K., Fier, N., Finn, R. D., Clarkson, B. D., Gee, T. S., Larson, S. M., Oettgen, H. E., and Old, L. J. A Phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: a specific bone marrow targeting and internalization of radionuclide. J. Clin. Oncol. 9: 478-490, 1991.
5. Schwartz, M. A., Lovett, D. R., Redner, A., Finn, R. D., Graham, M. C., Divgi, C. R., Dantis, L., Gee, T. S., Andreeff, M., Old, L. J., Larson, S. M., and Scheinberg, D. A. Dose escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J. Clin. Oncol., 11: 294-303, 1993.
6. Caron, P. C., Co, M. S., Bull, M. K., Avdalovic, N. M., and Scheinberg, D. A. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res., 52: 6761-6767, 1992.
7. Aaron, P. C., Jurcic, J. G., Scott, A. M., Finn, R. D., Divgi, C. R., Graham, M. C., Jureidini, I. M., Sgouros, G., Tyson, D., Old, L. J., Larson, S. M., and Scheinberg, D. A. A Phase Ib trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood, 83: 1760-1768, 1994.
8. Jurcic, J. G., DeBlasio, A., Dumont, L., Wan-ell, R. P., Jr., and Scheinberg, D. A. Molecular remission induction without relapse after anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Blood, 90: 416a, 1997.
9. Robertson, M. J., and Ritz, J. Biology and clinical relevance of human natural killer cells. Blood, 76: 2421-2438, 1990.
10. Rosenberg, S. A. The immunotherapy and gene therapy of cancer. J. Clin. Oncol., 10: 180-199, 1992.
11. Smith K. Lowest dose interleukin-2 immunotherapy. Blood, 81: 1414-1423, 1993.
12. Lista, P., Fierro, M. T., Xin-Sheng, L., Bonferroni, M., Brizzi, M. F., Porcu, P., Pegoraro, L., and Foa, R. Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukaemic stem cells. Eur. J. Haematol., 42: 425-430, 1989.
13. Adler, A., Chervenick, P. A., Whiteside, T. L., Lotzova, E., and Herberman, R. B. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. Blood, 71: 709-716, 1988.
14. Fierro, M. T., Xin-Sheng, L., Lusso P., Bonferroni, M., Matera, L., Cesano, A., Lista, P., Arione, R., Forni, G., and Foa, R. In vitro and in vivo susceptibility of human leukemia cells to lymphokine activated killer activity. Leukemia (Baltimore), 2: 50-54, 1988.
15. Gottlieb, D. J., Brenner, M. K., Heslop, H. E., Bianci, A. C. M., Bello-Fernandez, C., Mehta, A. B., Newland, A. C., Galazka, A. R., Scott, E. M., Hoffbrand, A. V., and Prentice, H. G. A Phase I clinical trial of recombinant interleukin 2 following high dose chemoradiotherapy for haematological malignancy: applicability to the elimination of residual disease. Br. J. Cancer, 60: 610-615, 1989.
16. Maraninchi, D., Blaise, D., Viens, P., Brandely, M., Olive, D., Lopez, M., Sainty, D., Marit, G., Stoppa, A. M., and Reiffers, J. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood, 78: 2182-2187, 1991.
17. Foa, R., Meloni, G., Tosti, S., Novarino, A., Fenu, S., Gavosto, F., and Mandelli, F. Treatment of acute myeloid leukaemia patients with recombinant interleukin-2: a pilot study. Br. J. Haematol., 77: 491-496, 1991.
18. Meloni, G., Foa, R., Vignett, M., Guarini, A., Fenu, S., Tosti, S., Gillio Tos, A., and Mandelli, F. Interleukin 2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood, 84: 2158-2163, 1994.
19. Lim, S. H., Newland, A. C., Kelsey, S., Bell, A., Offerman, E., Rist, C., Gozzard, D., Bareford, D., Smith, M. P., and Goldstone, A. H. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloif leukemia: a Phase II study. Cancer Immunol. Immunother., 34: 337-342, 1992.
20. Caligiuri, M., A., Murray, C., Soiffer, R. J., Klumpp, T. R., Seiden, M., Cochran, K., Cameron, C., Ish, C., Buchanan, L., Perillo, D., Smith, K., and Ritz, J. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J. Clin. Oncol. 9: 2110-2119, 1991.
21. Soiffer, R. J., Murray, C., Cochran, K., Cameron, C., Wang, E., Schow, P. W., Daley, J. F., and Ritz, J. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood, 79: 517-526, 1992.
22. Hank, J. A., Robinson, R. R., Surfus, J., Meuller, B. M., Resfeld, R. A., Cheung, N. K., Sondel, P. M. Augmentation of antibody-dependent, cell-mediated cytotoxicity following in vivo therapy with recombinant interleukin-2. Cancer Res. 50: 5234-5239, 1990.
23. Ortaldo, J. R., Woodhouse, C., Morgan, A. C., Herberman, R. B., Cheresh, D. A., and Reisfeld, R. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J. Immunol. 138: 3566-3572, 1987.
24. Munn, D. H., and Cheung, N. K. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res., 47: 6600-6605, 1987.
25. Biddle, W. C., Pancook, J., Goldrosen, M., Han, T., Foon, K. A., and Vaickus, L. Antibody-dependant, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effect of recombinant interleukin-2 on human effector cell lysis of human B-cell tumors. Cancer Res., 50: 2991-2996, 1990.
26. Junghans, R. P., Waldmann, T. A., Landolfi, N. F., Avdalovic, N. M., Schneider, W. P., and Queen, C. Anti-Tac-H, a humanized antbody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 50: 1495-1502, 1990.
27. Caron, P. C., Lai, L., and Scheinberg, D. A. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (HuM195) (anti-CD33) in myelogenous leukemia. Clin. Cancer Res., 1: 63-70, 1995.
28. Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Bodkin, D., Schilde, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T-M., Dellaire, B. K., Wey, K., Royston, I., Davis, T., and Levy, R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90: 2188-2195, 1997.
29. Caron, P. C., Dumont, L., and Scheinberg, D. A. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin. Cancer Res., 4: 1421-1428, 1998.
30. Feldman, E., Kalaycio, M., Schulman, P., Frankel, S., Weiner, G., Schwarzberg, L., Velez-Garcia, E., Jurcic, J., Scheinberg, D., and Wedel, N. Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia (AML): preliminary report of a Phase II study. Proc. Am. Soc. Clin. Oncol., 18: 12a, 1999.
31. Weisburg, J. H., Curcio, M., Caron, P. C., Gnapathirama, R., Mechetner, E., Roepe, P. D., and Scheinberg, D. A. The multidrug resistance (MDR) phenotype confers immunological resistance. J. Exp. Med., 183: 2699-2704, 1996.
32. Weisburg, J. H., Roepe, P. D., and Scheinberg, D. A. Intracellular pH (pHi) and multidrug resistance (MDR) regulate complement mediated cytotoxicity of nucleated human cells. J. Biol. Chem., 274:10877-10888, 1999.
33. Wagstaff, J. Lymphokines and cytokines. In: H. M. Pinedo, B. A. Chabner, and D. L. Longo (eds.), Cancer Chemotherapy and Biological Response Modifiers, Annual 12. Amsterdam: Elsevier Science Publishers, 1991.
34. Bukowski, R. M., McLain, D., and Finke, J. Clinical pharmacokinetics of interleukin 1, interleukin 2, interleukin 4, tumor necrosis factor, and macrophage colony-stimulating factor. In: B. A. Chabner, and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, Ed. 2. Philadelphia: Lippincott-Raven Publishers, 1996.
35. Hank, J. A., Surfus, J., Gan, J., et al. Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations. Clin. Cancer Res., 5: 281-289, 1999.